Objective: To evaluate the safety and efficacy of the RevoLix
120W 2 micron continuous wave laser vaporesection in the
treatment of benign prostatic hyperplasia (BPH).
Methods: We performed a retrospective chart review of 59 BPH
patients who underwent RevoLix 120W 2 micron continuous wave
laser vaporesection in our hospital from May 2010 to May 2011. The
average age of these patients was 74 years (range, 68 years to 95 years).
The operation duration, drop in hemoglobin, indwelling catheterization
time, operation-associated complications, international prostatic
symptom scores (IPSS), quality of life (QoL), urinary flow rate (Qmax),
and post voiding residual urine volume (PVR) were recorded.
Results: All 59 patients recovered without any incident. The mean
operative time was 58±23.2 min. Occasional venous hemorrhage
occurred during the operation, but no arterial hemorrhage was observed.
Hemoglobin decreased from preoperative 14.6 g/dL to postoperative
13.8 g/d (P<0.05). IPSS decreased from preoperative 20 ± 5.8 to
postoperative 8±4.2 (P<0.05), QoL scores decreased from 4.8±0.8 to
2.2±0.9 (P<0.05), Qmax increased from 7.9±4.8 to 20.6±10.3 mL/sec
(P<0.05), PVR decreased from 90.6±52.7 to 20.2±3.8 mL (P<0.05).
Conclusions: The RevoLix 120W 2-μm continuous wave laser
vaporesection is safe and effective in the treatment of BPH.